Febuxostat – A novel drug for treating hyperuricemia in goutPharmaffiliates Analytics and Synthetics Pvt. Ltd. Febuxostat is a recently approved medication used for the treatment of chronic gout and hyperuricemia. A non-purine, orally active selective inhibitor of xanthine oxidase, Febuxostat works by reducing the production of uric acid in the body. Gouty arthritis and hyperuricemia are the common diseases that have ailed humans for centuries. Febuxostat is effective in the treatment of mild-to-moderate renal/hepatic impairment with dramatic effects on the serum urate level. It can be safely used in patients with hypersensitivity reactions to allopurinol. With the rapid economic development, magnitude of diseases like gout have increases manifold times and there is an extensive need of medications like Febuxostat in the pharmaceutical world. Pharmaffiliates Analytics and Synthetics Pvt. Ltd., established in the 2005 is an eminent name worldwide as a leading manufacturer and supplier of active pharmaceutical ingredient (API), pharmaceutical impurity standard, pharmacopeial & non-pharmacopeial reference standards, drug gluconorides and metabolites, Isotope labelled reference standards, pesticides, Phytochemicals, agrochemicals and many more. Pharmaffiliates offers reference standard of Febuxostat and the impurities associated during the development stages of the drug. Details are listed below: Name of the product
Product Code
FEBUXOSTAT (API)
PA 06 61000
Febuxostat D7
PA D 40640
1285539-74-3
Febuxostat D9
PA D 40630
1246819-50-0
2-(3-CARBAMOYL-4ISOBUTOXYPHENYL)-4METHYLTHIAZOLE-5CARBOXYLIC ACID
PA 06 61510
2-ISOBUTOXY-5-(4METHYLTHIAZOL-2-YL) BENZONITRILE
PA 06 61520
2,2'-(4-ISOBUTOXY-1,3PHENYLENE)BIS(4METHYLTHIAZOLE-5CARBOXYLIC ACID)
PA 06 61530
ETHYL 2-(3-CYANO-4ISOBUTOXYPHENYL)-4METHYLTHIAZOLE-5CARBOXYLATE
PA 06 61540
160844-75-7
PA 06 61550
1346238-10-5
ISOPROPYL 2-(3-CYANO-4ISOBUTOXYPHENYL)-4METHYLTHIAZOLE-5-
1
CAS No. 144060-53-7
1239233-86-3
1335202-60-2
1330632-48-8